1. Home
  2. DAC vs CAPR Comparison

DAC vs CAPR Comparison

Compare DAC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Danaos Corporation

DAC

Danaos Corporation

HOLD

Current Price

$101.00

Market Cap

1.7B

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$24.13

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAC
CAPR
Founded
1972
2005
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
DAC
CAPR
Price
$101.00
$24.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$105.00
$41.38
AVG Volume (30 Days)
70.0K
1.3M
Earning Date
02-09-2026
11-10-2025
Dividend Yield
3.58%
N/A
EPS Growth
N/A
N/A
EPS
25.05
N/A
Revenue
$1,034,370,000.00
$11,130,509.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16,329.74
P/E Ratio
$4.02
N/A
Revenue Growth
2.90
N/A
52 Week Low
$65.40
$4.30
52 Week High
$102.20
$40.37

Technical Indicators

Market Signals
Indicator
DAC
CAPR
Relative Strength Index (RSI) 66.00 49.58
Support Level $98.41 $23.52
Resistance Level $101.72 $25.70
Average True Range (ATR) 2.04 1.63
MACD 0.30 -0.77
Stochastic Oscillator 90.52 15.86

Price Performance

Historical Comparison
DAC
CAPR

About DAC Danaos Corporation

Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: